Sci Trans med: Australian scientists have developed new drugs to prevent cardiovascular disease with significantly reduced side effects.

!---- Every year, one-third of the world's deaths are caused by cardiovascular disease, mainly heart attacks and strokesBoth diseases are caused by blood clots blocking blood vessels in the brain or the heartRecently, researchers at Monash University in Australia developed a new drug that prevents thrombosis and prevents cardiovascular disease attacksCurrent antithrombotic drugs have one major drawback: they prevent heart attacks by indiscriminately blocking platelet function, but increase the risk of heavy bleedingAlthough giving drugs such as aspirin at the onset of the disease can prevent further thrombosis, they only work in 25% of cases and can cause severe bleeding side effectsRecently, a team of researchers at Monash University in Australia found a way to target platelet activation, which specifically addresses the pathological reuniting of the blood without interfering with the normal hemostatic processThe study was published in science translational medicineEntitled "Disrupting the platelet internal internal computer via PI3KC2 alpha inhibition pertis pertinium pertis pertinium of canonical platelet" researchers found that inhibiting PI3KC2a protein can alter the reaction of platelets to changes in blood flow, which promotes the formation of blood clots, which is a common cause of thrombosis heart attack or strokeThe team first looked at small changes in platelets during a heart attackAmong them, the expression of the PI3KC2a gene in platelets attracted their attentionThe team found that mice that lacked PI3KC2a after genetic editing were able to completely prevent the formation of arterial thrombosis without affecting the hemorrhoid effectIt is well known that the PI3K-AKT-mTOR pathway is a target for cancer treatmentBut PI3KC2a, this class II PI3K, plays a role in platelets? The researchers used an electron microscope to cut ultra-thin "slices" of platelets from miceThey found that the inner membrane of platelets changed, and when blood flow changed, platelets did not gather or stick to each other or stick to the walls of blood vessels"It is this blood disturbance that is a sign and predictor of a heart attack," Justin Hamilton, senior author of the study, explained in a statementThis enzyme allows platelets to react to changes in blood flow and 'accelerates' the ability of platelets to clot, causing a heart attack"Following this, the researchers developed PI3KC2a inhibitors and further studied the main candidate drug MIPS-21335 They found that the drug had anti-thrombotic effects in human blood samples They then compared the drug to two commonly used antiplatelet drugs, aspirin and P2Y12 receptor inhibitors They found that MIPS-21335 remained effective when blood flow pressure increased on the surface of the blood vessels, and that both gold standard therapeutic drugs were less effective when it was stressed The team also reported that MIPS-21335 was effective in preventing thrombosis in mice and avoiding similar side effects compared to the side effects of aspirin that significantly increased blood loss and increased bleeding time Professor Hamilton said the next step was to develop a more suitable drug and put it into clinical trials, which he hopes will test in patients at higher risk of cardiovascular disease, such as people with diabetes Notably, it was also recently found that the drug developed by the research team was associated with the treatment of blood clots in COVID-19, and in response, "Although it is still in its early stages, we hope to explore the use of our newly developed antithrombotic drugs to improve the treatment of PATIENTs with COVID-19." "